Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : REP-0003
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Repair Biotech Wins FDA Orphan Drug Tag for Homozygous Familial Hypercholesterolemia
Details : REP-0003 is a cutting-edge messenger RNA therapy that clears harmful excess free cholesterol inside cells while preserving essential cholesterol, for homozygous familial hypercholesterolemia.
Product Name : REP-0003
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
May 19, 2025
Lead Product(s) : REP-0003
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : REP-0003
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Repair Biotech Announces Positive Pre-IND Meeting With FDA for REP-0003 in HoFH
Details : REP-0003 is based on company's LNP-mRNA CDP therapy, which is being evaluated in patients with homozygous familial hypercholesterolemia.
Product Name : REP-0003
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
January 21, 2025
Lead Product(s) : REP-0003
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable